✦ LIBER ✦

Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Scribed by Cono A. Ariti; John G.F. Cleland; Stuart J. Pocock; Marc A. Pfeffer; Karl Swedberg; Christopher B. Granger; John J.V. McMurray; Eric L. Michelson; Jan Östergren; Salim Yusuf

Book ID: 116192591
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 229 KB
Volume: 162
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2011.08.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prevention of atrial fibrillation in pat

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Anique Ducharme; Karl Swedberg; Marc A. Pfeffer; Alain Cohen-Solal; Christopher 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 238 KB

The data monitoring experience in the Ca

The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Stuart Pocock; Duolao Wang; Lars Wilhelmsen; Charles H. Hennekens 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Effects of Candesartan on Mortality and

Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure: The CHARM-Overall Programme

✍ Sricharan Kantipudi; Atul Khasnis 📂 Article 📅 2004 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 117 KB

Effects of candesartan on mortality and

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

✍ Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John JV McMurr 📂 Article 📅 2003 🏛 The Lancet 🌐 English ⚖ 129 KB

ACE Inhibitor Intolerance and Lessons Le

ACE Inhibitor Intolerance and Lessons Learned From the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Trials

✍ Domenic A. Sica 📂 Article 📅 2004 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 305 KB

Atrial Fibrillation and Risk of Clinical

Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction: Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program

✍ Lars G. Olsson; Karl Swedberg; Anique Ducharme; Christopher B. Granger; Eric L. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 431 KB